Małgorzata Bajor
Małgorzata Bajor
Mossakowski Medical Research Institute
Verified email at
Cited by
Cited by
Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer
K Marhelava, Z Pilch, M Bajor, A Graczyk-Jarzynka, R Zagozdzon
Cancers 11 (11), 1756, 2019
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen ReceptorsIntrinsic Functionality of NK Cells Affects CAR Retargeting
VYS Oei, M Siernicka, A Graczyk-Jarzynka, HJ Hoel, W Yang, D Palacios, ...
Cancer immunology research 6 (4), 467-480, 2018
Maintenance of long‐term potentiation in hippocampal mossy fiber—CA3 pathway requires fine‐tuned MMP‐9 proteolytic activity
G Wiera, G Wozniak, M Bajor, L Kaczmarek, JW Mozrzymas
Hippocampus 23 (6), 529-543, 2013
Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer
PC O’Leary, M Terrile, M Bajor, P Gaj, BT Hennessy, GB Mills, ...
Breast Cancer Research 16 (4), 1-15, 2014
Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma
A Trzeciecka, S Klossowski, M Bajor, R Zagozdzon, P Gaj, A Muchowicz, ...
Oncotarget 7 (2), 1717, 2016
Synaptic cell adhesion molecule‐2 and collapsin response mediator protein‐2 are novel members of the matrix metalloproteinase‐9 degradome
M Bajor, P Michaluk, P Gulyassy, AK Kekesi, G Juhasz, L Kaczmarek
Journal of neurochemistry 122 (4), 775-788, 2012
Proteolytic remodeling of the synaptic cell adhesion molecules (CAMs) by metzincins in synaptic plasticity
M Bajor, L Kaczmarek
Neurochemical research 38 (6), 1113-1121, 2013
Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents
M Bajor, AO Zych, A Graczyk-Jarzynka, A Muchowicz, M Firczuk, ...
British journal of cancer 119 (7), 873-884, 2018
Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate
A Graczyk-Jarzynka, A Goral, A Muchowicz, R Zagozdzon, M Winiarska, ...
Redox biology 21, 101062, 2019
Complement components, proteolysis‑related, and cell communication‑related proteins detected in urine proteomics are associated with IgA nephropathy.
K Mucha, M Bakun, R Jazwiec, M Dadlez, M Florczak, M Bajor, K Gala, ...
Polish archives of internal medicine 124 (7-8), 380-38, 2014
Adenanthin, a new inhibitor of thiol‐dependent antioxidant enzymes, impairs the effector functions of human natural killer cells
M Siernicka, M Winiarska, M Bajor, M Firczuk, A Muchowicz, M Bobrowicz, ...
Immunology 146 (1), 173-183, 2015
Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy
M Firczuk, M Bajor, A Graczyk-Jarzynka, K Fidyt, A Goral, R Zagozdzon
Cancer letters 471, 1-11, 2020
Application of genome editing techniques in immunology
AO Zych, M Bajor, R Zagozdzon
Archivum Immunologiae et Therapiae Experimentalis 66 (4), 289-298, 2018
An interplay of S-nitrosylation and metal ion binding for astrocytic S100B protein
M Bajor, M Zaręba-Kozioł, L Zhukova, K Goryca, J Poznański, ...
PloS one 11 (5), e0154822, 2016
The immune landscape of breast cancer: strategies for overcoming immunotherapy resistance
K Retecki, M Seweryn, A Graczyk-Jarzynka, M Bajor
Cancers 13 (23), 6012, 2021
Triple combination of ascorbate, menadione and the inhibition of peroxiredoxin-1 produces synergistic cytotoxic effects in triple-negative breast cancer cells
M Bajor, A Graczyk-Jarzynka, K Marhelava, M Kurkowiak, A Rahman, ...
Antioxidants 9 (4), 320, 2020
PRDX-1 supports the survival and antitumor activity of primary and CAR-modified NK cells under oxidative stress
M Klopotowska, M Bajor, A Graczyk-Jarzynka, A Kraft, Z Pilch, A Zhylko, ...
Cancer Immunology Research, 2021
Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells
J Chlebowska-Tuz, O Sokolowska, P Gaj, M Lazniewski, M Firczuk, ...
haematologica 103 (11), 1843, 2018
PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
M Bajor, A Graczyk-Jarzynka, K Marhelava, A Burdzinska, A Muchowicz, ...
Journal for immunotherapy of cancer 10 (1), 2022
Adenanthin, a new peroxiredoxin inhibitor, induces a switch between estrogen receptor alpha-mediated and Src/Akt-driven signaling in breast cancer cells
M Bajor, AO Zych, PC O'Leary, A Czekalska, WM Gallagher, J Golab, ...
The system can't perform the operation now. Try again later.
Articles 1–20